相关实验视频

Updated: May 10, 2025

Author Spotlight: Finding New Therapeutic Targets for Malignant Peripheral Nerve Sheath Tumor Through Genome-Scale shRNA Screens

Author Spotlight: Finding New Therapeutic Targets for Malignant Peripheral Nerve Sheath Tumor Through Genome-Scale shRNA Screens

Published on: August 25, 2023

通过虚拟查揭示有希望的PARP12抑制剂,用于癌症治疗

Sara Seifeldin¹, Mohd Saeed², Hanan Ali Alatawi³

¹Department of Clinical Laboratory Science, College of Applied Medical Science, University of Hail, Hail P.O. Box 2240, Saudi Arabia.

Current pharmaceutical design

|April 23, 2025

概括

研究人员确定了三种对Poly (ADP-ribose) 聚合酶12 (PARP12) 突变的强有力的小分子抑制剂. 这些化合物通过稳定DNA损伤反应途径,显示出针对癌症的前途.

科学领域:

生物化学生化学
分子生物学分子生物学
药理学药理学是指药理学的学科.

背景情况:

多 (ADP-ribose) 聚合酶12 (PARP12) 对于DNA损伤反应 (DDR) 和基因组稳定性至关重要.
PARP12突变与基因组不稳定性和癌症进展有关.
用小分子抑制剂向突变PARP12是一个治疗机会.

研究的目的:

为了确定对PARP12突变的强效抑制剂.
利用了NCI化合物库的分子对接和虚拟选.
使用分子动力学 (MD) 模拟验证的抑制剂结合稳定性.

主要方法:

开发了人类PARP12突变体的同质模型用于查.
采用分子对接来改进最高得分的化合物.
进行了全原子的MD模拟和MMGBSA计算,以评估结合稳定性和药物受体相互作用.

主要成果:

确定了三种有前途的抑制剂:NCI-32743,NCI-32982和NCI-659779.
这些化合物表现出高结合亲和力和与PARP12突变体的稳定相互作用.
ADMET和药理动力学分析表明具有有利的类似药物的特性.

结论:

已识别的抑制剂显示出在癌症治疗中向PARP12突变体的巨大潜力.
需要进一步的体外和体内研究来证实疗效.
这些化合物代表了针对PARP12突变癌症的临床开发的可行候选者.

关键词:

癌症癌症癌症癌症这是一种PARP12抑制剂.药物发现. 药物发现.分子对接的分子对接.分子动力学分子动力学

更多相关视频

Genome-wide RNAi Screening to Identify Host Factors That Modulate Oncolytic Virus Therapy

Genome-wide RNAi Screening to Identify Host Factors That Modulate Oncolytic Virus Therapy

Published on: April 3, 2018

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo

Published on: February 6, 2015

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Inhibition of Cdk Activity

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...